OTCMKTS:GNWSF StageZero Life Sciences (GNWSF) Stock Price, News & Analysis $0.02 0.00 (0.00%) As of 08/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About StageZero Life Sciences Stock (OTCMKTS:GNWSF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GNWSF alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.00▼$0.0352-Week Range$0.00▼$1.27VolumeN/AAverage Volume26,719 shsMarket Capitalization$1.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada. Read More Receive GNWSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address GNWSF Stock News HeadlinesStageZero Announces Partial Revocation of Cease Trade Order and Proposed FinancingMay 9, 2025 | stockhouse.comWave Life Sciences: Promising Growth with Strategic Innovations and Market ExpansionOctober 31, 2024 | markets.businessinsider.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 2 at 2:00 AM | Brownstone Research (Ad)5 things to know about the Texas Research Quarter, the life sciences hub planned for PlanoOctober 15, 2024 | msn.comChicago Beat: Looking at local life-sciences growth, Crafty gets new fundingOctober 11, 2024 | bizjournals.comNew Hampshire Life Sciences hosts Inaugural Live Free Life Science EventOctober 10, 2024 | yahoo.comHow Boy Meets World’s Ben Savage Views Maitland Ward's Porn CareerSeptember 25, 2024 | msn.comChicago Beat: NanoGraf expands footprint, what's next for life sciences in ChicagoSeptember 25, 2024 | bizjournals.comSee More Headlines GNWSF Stock Analysis - Frequently Asked Questions How have GNWSF shares performed this year? StageZero Life Sciences' stock was trading at $0.0016 at the start of the year. Since then, GNWSF shares have increased by 1,362.5% and is now trading at $0.0234. How do I buy shares of StageZero Life Sciences? Shares of GNWSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostic Substances Sub-IndustryN/A Current SymbolOTCMKTS:GNWSF CIK1454263 Webwww.stagezerolifesciences.com Phone905-209-2030FaxN/AEmployees80Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.86 million Net Margins-200.26% Pretax MarginN/A Return on EquityN/A Return on Assets-165.13% Debt Debt-to-Equity RatioN/A Current Ratio1.15 Quick Ratio1.08 Sales & Book Value Annual Sales$4.15 million Price / Sales0.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-1.17Miscellaneous Outstanding Shares62,995,000Free FloatN/AMarket Cap$1.47 million OptionableNot Optionable Beta0.28 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:GNWSF) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredDon’t Touch Tesla Stock Without Reading This FirstJeff Brown says he wouldn’t touch Tesla stock right now—and the reason might shock you. A 40-year Wall Stre...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding StageZero Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share StageZero Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.